IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
MWN-AI** Summary
IN8bio, a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies for cancer and autoimmune diseases, has announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin, who joined IN8bio as Chief Operating Officer in December 2021, has previously held roles as Vice President and Associate Vice President of Operations and Innovation since August 2020. Under her leadership, the company has made significant strides in advancing its clinical and preclinical pipeline, preparing for a new growth phase.
William Ho, CEO and Co-Founder of IN8bio, praised Dr. Rochlin's capabilities in aligning operational, manufacturing, clinical, and research teams, stating that her leadership has been pivotal in executing the company's strategic initiatives. Dr. Rochlin's extensive background spans more than 17 years in biotechnology, encompassing scientific research, intellectual property, business development, and clinical operations. Before IN8bio, she served as Chief Business Officer at Curadigm.
Notably, Dr. Rochlin has been integral to the advancement of IN8bio’s key programs, including INB-619, a potential first-in-class T cell engager aimed at deep B cell depletion in autoimmune diseases. Recent preclinical data showed that INB-619 achieved complete B cell depletion comparable to existing T cell engagers, while also demonstrating minimal adverse effects. Additionally, Dr. Rochlin has contributed to enhancing the company’s clinical manufacturing program, overseeing various Phase 1 and 2 clinical trials.
Expressing her excitement about her expanded role, Dr. Rochlin emphasized the importance of IN8bio's ongoing clinical advancements and expressed commitment to executing the company's priorities for long-term success.
MWN-AI** Analysis
IN8bio (Nasdaq: INAB) recently made headlines by promoting Dr. Kate Rochlin to President and Chief Operating Officer, a strategic move that underscores the company's commitment to advancing its clinical and preclinical pipeline. Dr. Rochlin's extensive experience in biotechnology, combined with her proven track record at IN8bio since December 2021, positions her ideally to lead the organization during a pivotal phase of growth.
From an investment perspective, there are several key takeaways that may indicate a favorable outlook for IN8bio. Firstly, the recent preclinical data for INB-619, highlighting its ability to achieve complete B cell depletion with minimal adverse effects, suggests promising efficacy that could attract increased investor interest. The validation of IN8bio’s T cell engager platform positions the company competitively in the oncology and autoimmune disease segments, which are lucrative markets.
Moreover, Dr. Rochlin’s leadership has already led to the advancement of multiple clinical programs, including those targeting glioblastoma and hematological cancers. Her expertise in quality control and regulatory compliance is likely to enhance operational efficiencies and reduce timeframes for getting products to market.
The current climate in biotechnology is characterized by a strong push for innovative therapies, especially those leveraging unique T cell capabilities. As IN8bio builds on its clinical successes and expands its pipeline, the potential for partnerships or acquisitions could further accelerate growth.
Investors should monitor IN8bio's upcoming clinical milestones and regulatory submissions, as these catalysts may drive stock volatility. The company’s focus on unmet medical needs aligns with broader industry trends, enhancing its attractiveness as part of a diversified portfolio.
In conclusion, with Dr. Rochlin at the helm and promising developments in its pipeline, IN8bio presents a compelling opportunity for investors looking to capitalize on advancements in biopharmaceuticals. However, as with all biotech investments, potential shareholders should be mindful of the inherent risks in clinical-stage companies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (?? ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately.
Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.
“Kate has been instrumental in translating IN8bio’s strategy into disciplined execution,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “Through her leadership and ability to align teams across operations, manufacturing, clinical, and research, she has played a central role in advancing our clinical programs, and T cell engager platform and delivering critical milestones on schedule. I am confident that her promotion to President will further strengthen the organization.”
Dr. Rochlin brings more than 17 years of experience across biotechnology company development, including scientific research, intellectual property, business development, clinical manufacturing and operations spanning corporate strategy, partnering, and team buildout. Prior to joining IN8bio, she was Chief Business Officer at Curadigm, a biotech developing precision-targeted drug delivery technologies, where she helped lead the company’s spin-out from Nanobiotix.
Since joining IN8bio, Dr. Rochlin has played a key role in advancing the company’s programs, including INB-619, a potential first-in-class, pan-?? T cell engager for deep B cell depletion in autoimmune disease. IN8bio recently presented preclinical data showing that INB-619 achieved complete B cell depletion comparable to approved T cell engagers, with minimal adverse cytokine release and robust expansion of ?? T cells. These results validate the differentiation of IN8bio’s T cell engager platform and support continued regulatory engagement and advancement toward the clinic. Dr. Rochlin has also been instrumental in developing and expanding IN8bio’s clinical manufacturing program, leading analytical, quality, regulatory and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers.
“I’m honored to take on this expanded role and broader leadership responsibilities at such an important time for IN8bio,” said Dr. Rochlin. “With encouraging clinical data emerging from our ?? T cell therapy programs and novel gamma-delta T cell engager technology, we are well positioned to build on this momentum. I look forward to continuing to work closely with our team to execute on our corporate priorities and position IN8bio for long-term success.”
Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducted research at Sloan Kettering Institute, and earned a BA in Biology from the University of Pennsylvania.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell product candidates for unmet medical needs. ?? T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic ?? T cells given to patients following a hematopoietic stem cell transplant. The Company is also evaluating autologous DeltEx DRI ?? T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel ?? T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/62811063-5de7-4e85-ab50-c1c32d410ea3
FAQ**
How does the promotion of Kate Rochlin, Ph.D., to President and COO impact the strategic direction of IN8bio Inc. INAB, particularly in advancing its clinical and preclinical pipeline?
What unique advantages do gamma-delta T cell therapies and T cell engagers offer in the competitive landscape of cancer and autoimmune disease treatments for IN8bio Inc. INAB?
Can you elaborate on the significance of the preclinical data achieved by INB-619 and its implications for IN8bio Inc. INAB's future clinical trials and market positioning?
How does IN8bio Inc. INAB plan to leverage Dr. Rochlin's extensive experience in biotechnology to enhance operational efficiencies and regulatory engagement as it moves toward its next phase of growth?
**MWN-AI FAQ is based on asking OpenAI questions about IN8bio Inc. (NASDAQ: INAB).
NASDAQ: INAB
INAB Trading
-5.04% G/L:
$1.65 Last:
2,542 Volume:
$1.65 Open:
